Tye, Mark A. http://orcid.org/0000-0002-9456-0767
Payne, N. Connor http://orcid.org/0000-0001-9513-6194
Johansson, Catrine
Singh, Kritika
Santos, Sofia A.
Fagbami, Lį»la
Pant, Akansha
Sylvester, Kayla http://orcid.org/0000-0003-4570-7432
Luth, Madeline R.
Marques, Sofia
Whitman, Malcolm
Mota, Maria M. http://orcid.org/0000-0002-2858-1041
Winzeler, Elizabeth A.
Lukens, Amanda K.
Derbyshire, Emily R. http://orcid.org/0000-0001-6664-8844
Oppermann, Udo
Wirth, Dyann F.
Mazitschek, Ralph http://orcid.org/0000-0002-1105-689X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI143723, R01AI152533)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | National Institutes of Health (F31AI129412, T32GM008666, S10OD026929)
Bill and Melinda Gates Foundation (OPP1054480)
National Science Foundation (DGE1745303)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Cancer Research UK (A23900)
Arthritis Research UK (20522)
Article History
Received: 11 December 2021
Accepted: 10 August 2022
First Online: 25 August 2022
Competing interests
: R.M. is a scientific advisory board (SAB) member and equity holder of Regenacy Pharmaceuticals, ERX Pharmaceuticals, and Frequency Therapeutics. M.A.T., N.C.P., D.F.W. and R.M. are inventors on patent applications related to this work. The remaining authors declare no competing interests.